• Explore /
  • Poster
  • / A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).

A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).

Abstract Poster

Authors

null

Jennifer Rachel Eads

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

Jennifer Rachel Eads , Stacey Stein , Anthony B. El-Khoueiry , Gulam Abbas Manji , Thomas Adam Abrams , Alok A. Khorana , Rebecca A. Miksad , Devalingam Mahalingam , Cynthia A. Sirard , Andrew X. Zhu , Lipika Goyal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT02375880

Citation

J Clin Oncol 35, 2017 (suppl; abstr 4075)

DOI

10.1200/JCO.2017.35.15_suppl.4075

Abstract #

4075

Poster Bd #

67

Abstract Disclosures

Similar Posters

First Author: John Ebben

First Author: Richard D. Kim

First Author: Jia Fan

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Varlitinib in combination with gemcitabine and cisplatin for treatment-naïve advanced biliary tract cancer.

Varlitinib in combination with gemcitabine and cisplatin for treatment-naïve advanced biliary tract cancer.

First Author: Do-Youn Oh